Zeria Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Zeria Pharmaceutical CEO'su Sachiaki Ibe, Jun2014 tarihinde atandı, in görev süresi 10.42 yıldır. şirketin hisselerinin 3.61% doğrudan sahiptir ve bu hisselerin değeri ¥ 3.67B dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 6.4 yıldır.

Anahtar bilgiler

Sachiaki Ibe

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	10.4yrs
CEO sahipliği	3.6%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality

May 21

Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00

Mar 15

CEO

Sachiaki Ibe (83 yo)

10.4yrs

Görev süresi

Mr. Sachiaki Ibe serves as the Chief Executive Officer and Chairman at Zeria Pharmaceutical Co., Ltd since June 2014 and served as its President since April 1982. Mr. Ibe served as Managing Director of Zer...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sachiaki Ibe	Chairman & CEO	10.4yrs	Veri yok	3.61% ¥ 3.7b
Mitsuhiro Ibe	President	10.4yrs	Veri yok	0.19% ¥ 191.2m
Yasuhisa Tanaka	Executive Officer and GM of Finance & Accounting Division	no data	Veri yok	Veri yok
Yoshihiro Hiraga	Executive Officer and GM of Research & Development Headquarters	11.4yrs	Veri yok	Veri yok
Hiroki Kato	Managing Executive Officer and GM of Asian Business	2.4yrs	Veri yok	Veri yok
Toshiaki Kawagoe	Executive Officer and GM of Reliability Assurance Headquarters & Customer Relations Office	no data	Veri yok	Veri yok
Kenji Kusano	Executive Officer & GM of Consumer Healthcare Sales Division	2.4yrs	Veri yok	Veri yok
Yuuki Okazawa	Managing Executive Officer & Director	2.4yrs	Veri yok	0.023% ¥ 23.0m
Mitsuru Iwai	Executive Officer & GM of Production & Logistics Headquarters	2.4yrs	Veri yok	Veri yok
Kazuhiro Akiba	Executive Officer & GM of Pharmaceutical Sales Division	2.4yrs	Veri yok	Veri yok
Kenichi Suzuki	Executive Officer and GM of Corporate Planning Division & Corporate Strategy Promotion Division	2.2yrs	Veri yok	Veri yok
Masakazu Sakurai	Executive Officer & Head of European Business Headquarters	1.8yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: 4559 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sachiaki Ibe	Chairman & CEO	52.7yrs	Veri yok	3.61% ¥ 3.7b
Mitsuhiro Ibe	President	14.4yrs	Veri yok	0.19% ¥ 191.2m
Yuuki Okazawa	Managing Executive Officer & Director	1.4yrs	Veri yok	0.023% ¥ 23.0m
Tetsuo Komori	Independent External Director	9.4yrs	Veri yok	0.016% ¥ 16.1m
Hirokazu Endo	Full-Time Audit & Supervisory Board Member	1.4yrs	Veri yok	0.18% ¥ 184.3m
Yukiko Naka	Outside Audit & Supervisory Board Member	21.4yrs	Veri yok	0.016% ¥ 16.1m
Kikuo Nomoto	Independent External Director	7.3yrs	Veri yok	Veri yok
Masaru Kamisuki	Outside Audit & Supervisory Board Member	5.4yrs	Veri yok	0.0023% ¥ 2.3m
Seiji Morimoto	Independent External Director	4.4yrs	Veri yok	0.0023% ¥ 2.3m
Hiroyuki Kuroda	Full-time Audit & Supervisory Board Member	less than a year	Veri yok	0.0023% ¥ 2.3m

6.4yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4559 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

Zeria Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024

Insufficient new directors

Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

No independent directors

Recent updates

Zeria Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 06, 2024

Upcoming dividend of JP¥23.00 per share

First quarter 2025 earnings released: EPS: JP¥95.55 (vs JP¥66.13 in 1Q 2024)

Final dividend of JP¥23.00 announced

Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality

Full year 2024 earnings: EPS misses analyst expectations

Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024

Zeria Pharmaceutical Co., Ltd. Provides Second Quarter and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2025

Upcoming dividend of JP¥22.00 per share

Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00

Zeria Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

Third quarter 2024 earnings released: EPS: JP¥68.67 (vs JP¥44.90 in 3Q 2023)

Zeria Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 01, 2024

Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings released: EPS: JP¥56.28 (vs JP¥31.64 in 2Q 2023)

Upcoming dividend of JP¥22.00 per share at 1.9% yield

Zeria Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

Zeria Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for the Six Months of 2024 and the Fiscal Year Ending March 31, 2024

Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2024

First quarter 2024 earnings released: EPS: JP¥66.13 (vs JP¥58.70 in 1Q 2023)

Insufficient new directors

Zeria Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

Consensus EPS estimates fall by 11%

Full year 2023 earnings: EPS misses analyst expectations

Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2023, Payable on June 30, 2023; Provides Second Quarter Dividend Guidance for the Full Year Ending March 31, 2024

Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Upcoming dividend of JP¥20.00 per share at 1.7% yield

Third quarter 2023 earnings released: EPS: JP¥44.90 (vs JP¥42.77 in 3Q 2022)

Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023

Zeria Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 02, 2023

Price target increased to JP¥2,700

Second quarter 2023 earnings released: EPS: JP¥31.64 (vs JP¥15.66 in 2Q 2022)

Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023

Upcoming dividend of JP¥18.00 per share

Zeria Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 02, 2022

First quarter 2023 earnings released: EPS: JP¥58.70 (vs JP¥30.89 in 1Q 2022)

Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter of the Year Ending March 31, 2023

Consensus forecasts updated

Zeria Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 04, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Zeria Pharmaceutical Co., Ltd. (TSE:4559) announces an Equity Buyback for 800,000 shares, representing 1.8% for ¥1,800 million.

Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

Price target increased to JP¥2,770

No independent directors

Zeria Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥17.00 per share

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥15.66 (vs JP¥8.97 in 2Q 2021)

Upcoming dividend of JP¥17.00 per share

Full year 2021 earnings released: EPS JP¥67.70 (vs JP¥62.62 in FY 2020)

Zeria Pharmaceutical Co., Ltd. (TSE:4559) announces an Equity Buyback for 800,000 shares, representing 1.75% for ¥1,800 million.

Price target increased to JP¥2,570

Upcoming dividend of JP¥17.00 per share

New 90-day high: JP¥2,192

Zeria Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

Analysts update estimates

Third quarter 2021 earnings released: EPS JP¥49.84 (vs JP¥23.89 in 3Q 2020)

Revenue and earnings miss expectations

New 90-day high: JP¥1,975

Zeria Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 05, 2021

Zeria Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 04, 2020

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş